Effects of probiotic supplementation on disease progression in patients with moderate to severe chronic kidney disease: a randomized controlled trial.
Samar Elshahat Saleh, Sherouk Salah Eldin Elnagar, Mohamed Ashraf Fouda et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the impact of Lactobacillus plantarum supplementation on disease progression in 72 patients with moderate to severe chronic kidney disease (CKD) stages 3 and 4. The study found that probiotic supplementation led to a significant increase in estimated glomerular filtration rate (eGFR), while the placebo group experienced a decline. Notably, no probiotic participants progressed in CKD compared to 8.6% in the placebo group.
Key findings
- Probiotic supplementation resulted in a significant increase in eGFR compared to a decline in the placebo group.
- No participants in the probiotic group experienced CKD progression, while 8.6% in the placebo group did.
- Treatment assignment was the sole independent predictor of eGFR change.
- Benefits were observed across CKD stages 3 and 4, and in both diabetic and non-diabetic patients.
Why it matters
The findings suggest that probiotics may offer a novel approach to slowing CKD progression, a significant concern given the limited therapeutic options available for patients in moderate stages of the disease.